Bolt Biotherapeutics (NASDAQ: BOLT) is a clinical-stage biopharmaceutical company that develops immuno-oncology therapies targeting myeloid biology. The company generates no product revenue, funding operations through equity issuances and, where available, external partnerships. Bolt was founded in 2015 based on research from the Engleman Laboratory at Stanford University. As of the 10-K filed March 12, 2026, William P. Quinn serves as President, Chief Executive Officer, and Chief Financial Officer. The company's pipeline centers on two approaches: the proprietary Boltbody ISAC (Immune-Stimulating Antibody Conjugate) platform and BDC-3042, a dectin-2 agonist antibody designed to repolarize tumor-associated macrophages from tumor-supportive to tumor-destructive states. BDC-3042 completed Phase 1 dose escalation, reporting a favorable safety profile and monotherapy anti-tumor activity in April 2025, but development is paused as of the filing date while the company seeks a partner or additional funding. The accumulated deficit position and ongoing net losses reflect a pre-commercial operation dependent on external capital.

Revenue model

No product revenue. The company is pre-commercial and finances operations through equity issuances, including common stock and an employee stock purchase plan, as reflected in the FY2025 and FY2024 stockholders' equity statements. Potential future revenue would come from partnership or licensing arrangements.

Products and services

Boltbody ISAC platform: proprietary immune-stimulating antibody conjugate approach targeting myeloid biology in the tumor microenvironment. BDC-3042: first-in-class dectin-2 agonist antibody; Phase 1 dose escalation completed with results reported April 2025; development paused pending partnering or additional funding as of the 10-K filed March 12, 2026.

Customers and end markets

No commercial customers as of the filing date. End market is oncology, specifically solid tumors addressed through myeloid immune mechanisms. Future customers would be cancer patients and the healthcare institutions treating them.

Value-chain role

Early-stage drug discoverer and clinical developer. Bolt originates programs internally from academic research (Stanford Engleman Laboratory), advances them through preclinical and Phase 1 clinical trials, and seeks external partners for further development and commercialization.

Source: SEC 10-K, filed 2026-03-12

Industry: Pharmaceutical Preparations Peers: Cardiff Oncology Inc Curis Inc Cyteir Therapeutics, Inc. Equillium Inc Korro Bio Inc Synlogic Inc Pyxis Oncology Inc TCR2 THERAPEUTICS INC. SQZ Biotechnologies Co